机译:设计,合成和生物学评估作为新型p21活化激酶4(PAK4)抑制剂的菲基-四氢异喹啉衍生物
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang 110001, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang 110001, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang 110001, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
机译:基于结构的6-氯-4-氨基喹唑啉-2-甲酰胺衍生物的设计为有效和选择性P21-活化激酶4(PAK4)抑制剂
机译:设计,合成和生物学评估氨基吡嗪衍生物作为有丝分裂原激活的蛋白激酶激活的蛋白激酶2(MK-2)的抑制剂
机译:N-烷基或芳基取代的异靛蓝衍生物作为潜在的双重细胞周期蛋白依赖性激酶2(CDK2)/糖原合酶激酶30(GSK-3P)磷酸化抑制剂的设计,合成和生物学评估
机译:一些新型欧尔替尼衍生物的设计与合成潜在EGFR激酶抑制剂
机译:药物化学中基于结构的药物设计:I.跨病变合成抑制剂的开发II。磺酰哌嗪衍生物对LpxH的抑制作用及其合成及生物学评价
机译:新型喹喔啉衍生物作为双PIM-1/2激酶抑制剂:设计合成和生物学评估
机译:基于结构的6-氯-4-氨基喹唑啉-2-甲酰胺衍生物的设计为有效和选择性P21-活化激酶4(PAK4)抑制剂